Table 1.
Descriptive characteristics of the patient population (n=1,114)
| Variable | N | Percent (%) |
|---|---|---|
| Age at diagnosis | ||
| ≤ 50 years | 388 | 34.8 |
| >50 years | 726 | 65.2 |
| Race | ||
| Caucasian | 962 | 86.4 |
| African American | 135 | 12.1 |
| Other | 17 | 1.5 |
| Tumor size | ||
| T1 (≤2 cm) | 609 | 55.7 |
| T2 (2-5 cm) | 411 | 37.6 |
| T3 (>5 cm) | 73 | 6.7 |
| Lymph node | ||
| N0 (0 positive nodes) | 570 | 54 |
| N1 (1-3 positive nodes) | 293 | 27.7 |
| N2 (4-9 positive nodes) | 118 | 11.2 |
| N3 (≥10 positive nodes) | 75 | 7.1 |
| ER | ||
| Negative | 321 | 28.9 |
| Positive | 790 | 71.1 |
| PR | ||
| Negative | 480 | 43.2 |
| Positive | 631 | 56.8 |
| Her2/neu | ||
| Negative | 842 | 76.3 |
| Strong | 217 | 19.7 |
| Weak | 44 | 4 |
| Clinical subtype | ||
| Luminal A | 615 | 55.9 |
| Luminal B | 180 | 16.3 |
| Her2 enriched | 80 | 7.3 |
| Triple negative | 226 | 20.5 |
| Ki-67 | ||
| Low (<15%) | 467 | 66.8 |
| Moderate (16-30%) | 121 | 17.3 |
| High (>30%) | 111 | 15.9 |
| VDR expression by IHC | ||
| Low (IRS=0-2) | 477 | 42.8 |
| Moderate (IRS=3-5) | 354 | 31.8 |
| Strong (IRS=6-12) | 283 | 25.4 |
Footnote: For some variables, the total number does not add up to the total of 1,114 due to missing data.
Abbreviation: IRS, immunoereactive score; ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor 2.